BD Soluvia™ is a prefillable microinjection system that is integrated with a tiny BD™ microneedle. It allows a drug or vaccine to be accurately delivered intradermally. This has proven to offer a simple, reliable delivery method.
The dermal layer contains a dense network of lymphatic vessels feeding local lymph nodes, resulting in rapid and efficient therapeutic response. It also contains a high concentration of potent immune cells that play a key role to initiate the immune response following vaccination.
Independently, BD conducted clinical trials involving more than 700 subjects and 3500 injections with BD Soluvia, and demonstrated that the system was safe and easy to use.(1)
Clinical testing showed that the BD Microneedle is barely perceptible when it enters the skin and ensures the administration of the injected solution to the dermal layer irrespective of the subject’s gender, age, ethnicity and body mass.(2)
1. Laurent P, et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine. 2007;25; 8833-8842
2. Laurent P, et al. Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines. Vaccine. 2007;25:6423-30
Sales or transfers of products by BD Medical - Pharmaceutical Systems are only made expressly subject to our Standard Terms and Conditions of Sale which can be accessed on-line for the United States, and for Europe, the Middle East and Africa. Terms and Conditions of Sale applicable to transactions elsewhere in the world may be accessed either from our Contact Us page or from the BD entity selling or providing such products.